Tryp Therapeutics

Tryp Therapeutics is a clinical-stage biotechnology firm focused on creating psilocybin-related compounds, including TRP-8803, for the treatment of diseases with unmet medical needs through accelerated regulatory pathways.

Tryp's Psilocybin-For-Neuropsychiatric Disorders (PFN™) project is concerned with the creation of synthetic psilocybin-related molecules as a new kind of medication for the treatment of binge eating, chronic pain, and other indications.

The University of Florida has begun enrolling subjects in collaboration with Tryp Therapeutics for a Phase II study for binge eating disorder, and Tryp Therapeutics also announced an upcoming Phase IIa clinical trial at the University of Michigan to test TRP-8802 for fibromyalgia.

Tryp Therapeutics TRP-8803 is a novel psilocybin-based drug that, through a new formulation and mode of administration, may improve efficacy, safety, and patient experience.

Psychedelic News